L-type voltage-dependent calcium channels as therapeutic targets for neurodegenerative diseases

Current Medicinal Chemistry

Volumn 19, Issue 28, 2012, Pages 4816-4827

  Yagami, T ^a   Kohma, H ^a   Yamamoto, Y ^a  

^a HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; L type voltage dependent Ca2+ channels; Long term potentiation; Neurodegenerative diseases; Phospholipase A2; Vascular dementia

Indexed keywords

4,7 DIHYDRO 3 ISOBUTYL 6 METHYL 4 (3 NITROPHENYL)THIENO[2,3 B]PYRIDINE 5 CARBOXYLIC ACID METHYL ESTER; AMYLOID BETA PROTEIN; BAYK 8644; BENZOTHIAZEPINE DERIVATIVE; CALCICLUDINE; CALCISEPTINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; DILTIAZEM; MIBEFRADIL; NIFEDIPINE; NIMODIPINE; OMEGA AGATOXIN IVA; OMEGA CONOTOXIN GVIA; OMEGA CONOTOXIN MVIIC; PHENYLALKYLAMINE; SNAKE VENOM; SNX 482; TAICATOXIN; UNCLASSIFIED DRUG; VERAPAMIL;

ALZHEIMER DISEASE; ARTICLE; CALCIUM SIGNALING; DEGENERATIVE DISEASE; DENDRITE; DRUG TARGETING; GENE EXPRESSION; HUMAN; KNOCKOUT MOUSE; MULTIINFARCT DEMENTIA; NERVE CELL; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRION DISEASE; SPINE;

ALZHEIMER DISEASE; ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; DEMENTIA; HUMANS; ION TRANSPORT; NEURODEGENERATIVE DISEASES; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; PRION DISEASES; RISK FACTORS;

EID: 84870417658     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803341430     Document Type: Article

References (121)

1. Pozzan, T.; Rizzuto, R.; Volpe, P.; Meldolesi, J. Molecular and cellular physiology of intracellular calcium stores. Physiol. Rev., 1994, 74, 595-636.
2. Dai, S.; Hall, D. D.; Hell, J. W. Supramolecular assemblies and localized regulation of voltage-gated ion channels. Physiol. Rev., 2009, 89, 411-52.
3. Dolphin, A. C. Calcium channel diversity: multiple roles of calcium channel subunits. Curr. Opin. Neurobiol., 2009, 19, 237-44.
4. Iftinca, M. C.; Zamponi, G. W. Regulation of neuronal T-type calcium channels. Trends. Pharmacol. Sci., 2009, 30, 32-40.
5. Catterall, W. A.; Perez-Reyes, E.; Snutch, T. P.; Striessnig, J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev., 2005, 57, 411-25.
6. van der Heyden, M. A.; Wijnhoven, T. J.; Opthof, T. Molecular aspects of adrenergic modulation of cardiac L-type Ca2+ channels. Cardiovasc. Res., 2005, 65, 28-39.
7. Bunemann, M.; Gerhardstein, B. L.; Gao, T.; Hosey, M. M. Functional regulation of L-type calcium channels via protein kinase A-mediated phosphorylation of the beta(2) subunit. J Biol Chem, 1999, 274, 33851-4.
8. Kochlamazashvili, G.; Henneberger, C.; Bukalo, O.; Dvoretskova, E.; Senkov, O.; Lievens, P. M.; Westenbroek, R.; Engel, A. K.; Catterall, W. A.; Rusakov, D. A.; Schachner, M.; Dityatev, A. The extracellular matrix molecule hyaluronic acid regulates hippocampal synaptic plasticity by modulating postsynaptic L-type Ca(2+) channels. Neuron, 2010, 67, 116-28.
9. Mize, R. R.; Graham, S. K.; Cork, R. J. Expression of the L-type calcium channel in the developing mouse visual system by use of immunocytochemistry. Brain Res. Dev. Brain Res., 2002, 136, 185-95.
10. Hell, J. W.; Westenbroek, R. E.; Warner, C.; Ahlijanian, M. K.; Prystay, W.; Gilbert, M. M.; Snutch, T. P.; Catterall, W. A. Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits. J Cell Biol, 1993, 123, 949-62.
11. Tippens, A. L.; Pare, J. F.; Langwieser, N.; Moosmang, S.; Milner, T. A.; Smith, Y.; Lee, A. Ultrastructural evidence for pre- and postsynaptic localization of Cav1.2 L-type Ca2+ channels in the rat hippocampus. J Comp Neurol, 2008, 506, 569-83.
12. Westenbroek, R. E.; Hoskins, L.; Catterall, W. A. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J. Neurosci., 1998, 18, 6319-30.
13. Murphy, T. H.; Worley, P. F.; Baraban, J. M. L-type voltage-sensitive calcium channels mediate synaptic activation of immediate early genes. Neuron, 1991, 7, 625-35.
14. Bading, H.; Ginty, D. D.; Greenberg, M. E. Regulation of gene expression in hippocampal neurons by distinct calcium signaling pathways. Science, 1993, 260, 181-6.
15. Moosmang, S.; Haider, N.; Klugbauer, N.; Adelsberger, H.; Langwieser, N.; Muller, J.; Stiess, M.; Marais, E.; Schulla, V.; Lacinova, L.; Goebbels, S.; Nave, K. A.; Storm, D. R.; Hofmann, F.; Kleppisch, T. Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J. Neurosci., 2005, 25, 9883-92.
16. Bliss, T. V.; Collingridge, G. L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 1993, 361, 31-9.
17. Martin, K. C.; Barad, M.; Kandel, E. R. Local protein synthesis and its role in synapse-specific plasticity. Curr. Opin. Neurobiol., 2000, 10, 587-92.
18. Grover, L. M.; Teyler, T. J. Two components of long-term potentiation induced by different patterns of afferent activation. Nature, 1990, 347, 477-9.
19. Bolshakov, V. Y.; Siegelbaum, S. A. Postsynaptic induction and presynaptic expression of hippocampal long-term depression. Science, 1994, 264, 1148-52.
20. Morgan, S. L.; Teyler, T. J. VDCCs and NMDARs underlie two forms of LTP in CA1 hippocampus in vivo. J. Neurophysiol., 1999, 82, 736-40.
21. Niikura, Y.; Abe, K.; Misawa, M. Involvement of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral amygdala-dentate gyrus pathway of anesthetized rats. Brain Res., 2004, 1017, 218-21.
22. Borroni, A. M.; Fichtenholtz, H.; Woodside, B. L.; Teyler, T. J. Role of voltage-dependent calcium channel long-term potentiation (LTP) and NMDA LTP in spatial memory. J. Neurosci., 2000, 20, 9272-6.
23. Bauer, E. P.; Schafe, G. E.; LeDoux, J. E. NMDA receptors and L-type voltage-gated calcium channels contribute to long-term potentiation and different components of fear memory formation in the lateral amygdala. J. Neurosci., 2002, 22, 5239-49.
24. Woodside, B. L.; Borroni, A. M.; Hammonds, M. D.; Teyler, T. J. NMDA receptors and voltage-dependent calcium channels mediate different aspects of acquisition and retention of a spatial memory task. Neurobiol. Learn. Mem., 2004, 81, 105-14.
25. Lashgari, R.; Motamedi, F.; Zahedi Asl, S.; Shahidi, S.; Komaki, A. Behavioral and electrophysiological studies of chronic oral administration of Ltype calcium channel blocker verapamil on learning and memory in rats. Behav. Brain Res., 2006, 171, 324-8.
26. Dolmetsch, R. E.; Pajvani, U.; Fife, K.; Spotts, J. M.; Greenberg, M. E. Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science, 2001, 294, 333-9.
27. Peterson, B. Z.; DeMaria, C. D.; Adelman, J. P.; Yue, D. T. Calmodulin is the Ca2+ sensor for Ca2+ -dependent inactivation of L-type calcium channels. Neuron, 1999, 22, 549-58.
28. Zuhlke, R. D.; Pitt, G. S.; Deisseroth, K.; Tsien, R. W.; Reuter, H. Calmodulin supports both inactivation and facilitation of L-type calcium channels. Nature, 1999, 399, 159-62.
29. Davare, M. A.; Avdonin, V.; Hall, D. D.; Peden, E. M.; Burette, A.; Weinberg, R. J.; Horne, M. C.; Hoshi, T.; Hell, J. W. A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2. Science, 2001, 293, 98-101.
30. Budd, S. L.; Tenneti, L.; Lishnak, T.; Lipton, S. A. Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 6161-6.
31. Ghosh, A.; Ginty, D. D.; Bading, H.; Greenberg, M. E. Calcium regulation of gene expression in neuronal cells. J. Neurobiol., 1994, 25, 294-303.
32. Geiger, J. R.; Melcher, T.; Koh, D. S.; Sakmann, B.; Seeburg, P. H.; Jonas, P.; Monyer, H. Relative abundance of subunit mRNAs determines gating and Ca2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron, 1995, 15, 193-204.
33. Berridge, M. J. Neuronal calcium signaling. Neuron, 1998, 21, 13-26.
34. Ray, S. K.; Banik, N. L. Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr. Drug Targets CNS Neurol. Disord., 2003, 2, 173-89.
35. Black, S. E. Vascular dementia. Stroke risk and sequelae define therapeutic approaches. Postgrad. Med., 2005, 117, 15-6, 19-25.
36. in't Veld, B. A.; Ruitenberg, A.; Hofman, A.; Stricker, B. H.; Breteler, M. M. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol. Aging, 2001, 22, 407-12.
37. Schehr, R. S. New treatments for acute stroke. Nat. Biotechnol., 1996, 14, 1549-54.
38. Umemura, K.; Kawai, H.; Ishihara, H.; Nakashima, M. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. Jpn. J. Pharmacol., 1995, 67, 253-8.
39. Hallenbeck, J. M. Blood-damaged tissue interaction in experimental brain ischemia. Acta. Neurochir. Suppl. (Wien), 1994, 60, 233-7.
40. Li, Y.; Sharov, V. G.; Jiang, N.; Zaloga, C.; Sabbah, H. N.; Chopp, M. Ultrastructural and light microscopic evidence of apoptosis after middle cerebral artery occlusion in the rat. Am. J. Pathol., 1995, 146, 1045-51.
41. Yagami, T. Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia. Curr. Neuropharmacol., 2006, 4, 87-100.
42. Taketo, M. M.; Sonoshita, M. Phospolipase A2 and apoptosis. Biochim. Biophys. Acta, 2002, 1585, 72-6.
43. Yagami, T.; Ueda, K.; Asakura, K.; Hata, S.; Kuroda, T.; Sakaeda, T.; Takasu, N.; Tanaka, K.; Gemba, T.; Hori, Y. Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol. Pharmacol., 2002, 61, 114-26.
44. Yagami, T.; Ueda, K.; Asakura, K.; Hayasaki-Kajiwara, Y.; Nakazato, H.; Sakaeda, T.; Hata, S.; Kuroda, T.; Takasu, N.; Hori, Y. Group IB secretory phospholipase A2 induces neuronal cell death via apoptosis. J. Neurochem., 2002, 81, 449-61.
45. Yagami, T.; Ueda, K.; Asakura, K.; Hata, S.; Kuroda, T.; Sakaeda, T.; Kishino, J.; Sakaguchi, G.; Itoh, N.; Hori, Y. Group IB secretory phospholipase A(2)induces cell death in the cultured cortical neurons: a possible involvement of its binding sites. Brain Res., 2002, 949, 197-201.
46. Lin, T. N.; Wang, Q.; Simonyi, A.; Chen, J. J.; Cheung, W. M.; He, Y. Y.; Xu, J.; Sun, A. Y.; Hsu, C. Y.; Sun, G. Y. Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain. J. Neurochem., 2004, 90, 637-45.
47. Yagami, T.; Ueda, K.; Asakura, K.; Sakaeda, T.; Hata, S.; Kuroda, T.; Sakaguchi, G.; Itoh, N.; Hashimoto, Y.; Hori, Y. Porcine pancreatic group IB secretory phospholipase A2 potentiates Ca2+ influx through L-type voltagesensitive Ca2+ channels. Brain Res., 2003, 960, 71-80.
48. Yagami, T.; Ueda, K.; Asakura, K.; Nakazato, H.; Hata, S.; Kuroda, T.; Sakaeda, T.; Sakaguchi, G.; Itoh, N.; Hashimoto, Y.; Hori, Y. Human group IIA secretory phospholipase A2 potentiates Ca2+ influx through L-type voltage- sensitive Ca2+ channels in cultured rat cortical neurons. J. Neurochem., 2003, 85, 749-58.
49. Wisniewski, T.; Frangione, B. Molecular biology of brain aging and neurodegenerative disorders. Acta Neurobiol. Exp. (Wars), 1996, 56, 267-79.
50. Moses, G. S.; Jensen, M. D.; Lue, L. F.; Walker, D. G.; Sun, A. Y.; Simonyi, A.; Sun, G. Y. Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J. Neuroinflammation, 2006, 3, 28.
51. Levy, E.; Carman, M. D.; Fernandez-Madrid, I. J.; Power, M. D.; Lieberburg, I.; van Duinen, S. G.; Bots, G. T.; Luyendijk, W.; Frangione, B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science, 1990, 248, 1124-6.
52. Pinessi, L.; Rainero, I.; Brunetti, E.; Cerrato, P.; Cosentino, N.; Martino, C.; Vaula, G.; Bergamini, L. [The genetics of Alzheimer's disease]. Minerva Psichiatr, 1992, 33, 159-64.
53. Levy-Lahad, E.; Wasco, W.; Poorkaj, P.; Romano, D. M.; Oshima, J.; Pettingell, W. H.; Yu, C. E.; Jondro, P. D.; Schmidt, S. D.; Wang, K.; et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science, 1995, 269, 973-7.
54. Corder, E. H.; Saunders, A. M.; Strittmatter, W. J.; Schmechel, D. E.; Gaskell, P. C.; Small, G. W.; Roses, A. D.; Haines, J. L.; Pericak-Vance, M. A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993, 261, 921-3.
55. Green, K. N.; Demuro, A.; Akbari, Y.; Hitt, B. D.; Smith, I. F.; Parker, I.; LaFerla, F. M. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Gen Physiol, 2008, 132, i1.
56. Cheung, K. H.; Shineman, D.; Muller, M.; Cardenas, C.; Mei, L.; Yang, J.; Tomita, T.; Iwatsubo, T.; Lee, V. M.; Foskett, J. K. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron, 2008, 58, 871-83.
57. Rybalchenko, V.; Hwang, S. Y.; Rybalchenko, N.; Koulen, P. The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int J Biochem Cell Biol, 2008, 40, 84-97.
58. Zampese, E.; Fasolato, C.; Kipanyula, M. J.; Bortolozzi, M.; Pozzan, T.; Pizzo, P. Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk. Proc Natl Acad Sci U S A, 2011, 108, 2777-82.
59. Veinbergs, I.; Everson, A.; Sagara, Y.; Masliah, E. Neurotoxic effects of apolipoprotein E4 are mediated via dysregulation of calcium homeostasis. J Neurosci Res, 2002, 67, 379-87.
60. Bezprozvanny, I.; Mattson, M. P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci, 2008, 31, 454-63.
61. Ueda, K.; Shinohara, S.; Yagami, T.; Asakura, K.; Kawasaki, K. Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals. J. Neurochem., 1997, 68, 265-71.
62. Mattson, M. P.; Cheng, B.; Davis, D.; Bryant, K.; Lieberburg, I.; Rydel, R. E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci, 1992, 12, 376-89.
63. Martinez-Coria, H.; Green, K. N.; Billings, L. M.; Kitazawa, M.; Albrecht, M.; Rammes, G.; Parsons, C. G.; Gupta, S.; Banerjee, P.; LaFerla, F. M. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol, 2010, 176, 870-80.
64. Ueda, K.; Fukui, Y.; Kageyama, H. Amyloid beta protein-induced neuronal cell death: neurotoxic properties of aggregated amyloid beta protein. Brain Res., 1994, 639, 240-4.
65. Nunomura, A.; Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, E. K.; Jones, P. K.; Ghanbari, H.; Wataya, T.; Shimohama, S.; Chiba, S.; Atwood, C. S.; Petersen, R. B.; Smith, M. A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2001, 60, 759-67.
66. Paola, D.; Domenicotti, C.; Nitti, M.; Vitali, A.; Borghi, R.; Cottalasso, D.; Zaccheo, D.; Odetti, P.; Strocchi, P.; Marinari, U. M.; Tabaton, M.; Pronzato, M. A. Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem. Biophys. Res. Commun., 2000, 268, 642-6.
67. Hurley, M. J.; Dexter, D. T. Voltage-gated calcium channels and Parkinson's disease. Pharmacol Ther, 2011, in press.
68. Jellinger, K. A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol, 1991, 14, 153-97.
69. Grace, A. A.; Bunney, B. S. The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci., 1984, 4, 2877-90.
70. Romo, R.; Schultz, W. Dopamine neurons of the monkey midbrain: contingencies of responses to active touch during self-initiated arm movements. J. Neurophysiol., 1990, 63, 592-606.
71. Bonci, A.; Grillner, P.; Mercuri, N. B.; Bernardi, G. L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons. J. Neurosci., 1998, 18, 6693-703.
72. Wilson, C. J.; Callaway, J. C. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J. Neurophysiol., 2000, 83, 3084-100.
73. Striessnig, J.; Koschak, A.; Sinnegger-Brauns, M. J.; Hetzenauer, A.; Nguyen, N. K.; Busquet, P.; Pelster, G.; Singewald, N. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem. Soc. Trans., 2006, 34, 903-9.
74. Sinnegger-Brauns, M. J.; Huber, I. G.; Koschak, A.; Wild, C.; Obermair, G. J.; Einzinger, U.; Hoda, J. C.; Sartori, S. B.; Striessnig, J. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol. Pharmacol., 2009, 75, 407-14.
75. Chan, C. S.; Guzman, J. N.; Ilijic, E.; Mercer, J. N.; Rick, C.; Tkatch, T.; Meredith, G. E.; Surmeier, D. J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature, 2007, 447, 1081-6.
76. Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E. S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W. G.; Lazzarini, A. M.; Duvoisin, R. C.; Di Iorio, G.; Golbe, L. I.; Nussbaum, R. L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276, 2045-7.
77. Paisan-Ruiz, C.; Jain, S.; Evans, E. W.; Gilks, W. P.; Simon, J.; van der Brug, M.; Lopez de Munain, A.; Aparicio, S.; Gil, A. M.; Khan, N.; Johnson, J.; Martinez, J. R.; Nicholl, D.; Carrera, I. M.; Pena, A. S.; de Silva, R.; Lees, A.; Marti-Masso, J. F.; Perez-Tur, J.; Wood, N. W.; Singleton, A. B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 2004, 44, 595-600.
78. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 1998, 392, 605-8.
79. Valente, E. M.; Abou-Sleiman, P. M.; Caputo, V.; Muqit, M. M.; Harvey, K.; Gispert, S.; Ali, Z.; Del Turco, D.; Bentivoglio, A. R.; Healy, D. G.; Albanese, A.; Nussbaum, R.; Gonzalez-Maldonado, R.; Deller, T.; Salvi, S.; Cortelli, P.; Gilks, W. P.; Latchman, D. S.; Harvey, R. J.; Dallapiccola, B.; Auburger, G.; Wood, N. W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 2004, 304, 1158-60.
80. Bonifati, V.; Rizzu, P.; van Baren, M. J.; Schaap, O.; Breedveld, G. J.; Krieger, E.; Dekker, M. C.; Squitieri, F.; Ibanez, P.; Joosse, M.; van Dongen, J. W.; Vanacore, N.; van Swieten, J. C.; Brice, A.; Meco, G.; van Duijn, C. M.; Oostra, B. A.; Heutink, P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 2003, 299, 256-9.
81. Ramirez, A.; Heimbach, A.; Grundemann, J.; Stiller, B.; Hampshire, D.; Cid, L. P.; Goebel, I.; Mubaidin, A. F.; Wriekat, A. L.; Roeper, J.; Al-Din, A.; Hillmer, A. M.; Karsak, M.; Liss, B.; Woods, C. G.; Behrens, M. I.; Kubisch, C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet, 2006, 38, 1184-91.
82. Yoshino, H.; Tomiyama, H.; Tachibana, N.; Ogaki, K.; Li, Y.; Funayama, M.; Hashimoto, T.; Takashima, S.; Hattori, N. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology, 2010, 75, 1356-61.
83. Di Fonzo, A.; Dekker, M. C.; Montagna, P.; Baruzzi, A.; Yonova, E. H.; Correia Guedes, L.; Szczerbinska, A.; Zhao, T.; Dubbel-Hulsman, L. O.; Wouters, C. H.; de Graaff, E.; Oyen, W. J.; Simons, E. J.; Breedveld, G. J.; Oostra, B. A.; Horstink, M. W.; Bonifati, V. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology, 2009, 72, 240-5.
84. Schapira, A. H.; Cooper, J. M.; Dexter, D.; Jenner, P.; Clark, J. B.; Marsden, C. D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet, 1989, 1, 1269.
85. Kahle, P. J.; Waak, J.; Gasser, T. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med, 2009, 47, 1354-61.
86. Narendra, D. P.; Jin, S. M.; Tanaka, A.; Suen, D. F.; Gautier, C. A.; Shen, J.; Cookson, M. R.; Youle, R. J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol, 2010, 8, e1000298.
87. Martinez-Vicente, M.; Talloczy, Z.; Kaushik, S.; Massey, A. C.; Mazzulli, J.; Mosharov, E. V.; Hodara, R.; Fredenburg, R.; Wu, D. C.; Follenzi, A.; Dauer, W.; Przedborski, S.; Ischiropoulos, H.; Lansbury, P. T.; Sulzer, D.; Cuervo, A. M. Dopamine-modified alpha-synuclein blocks chaperonemediated autophagy. J Clin Invest, 2008, 118, 777-88.
88. Hettiarachchi, N. T.; Parker, A.; Dallas, M. L.; Pennington, K.; Hung, C. C.; Pearson, H. A.; Boyle, J. P.; Robinson, P.; Peers, C. alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem, 2009, 111, 1192-201.
89. Nath, S.; Goodwin, J.; Engelborghs, Y.; Pountney, D. L. Raised calcium promotes alpha-synuclein aggregate formation. Mol Cell Neurosci, 2011, 46, 516-26.
90. Mosharov, E. V.; Larsen, K. E.; Kanter, E.; Phillips, K. A.; Wilson, K.; Schmitz, Y.; Krantz, D. E.; Kobayashi, K.; Edwards, R. H.; Sulzer, D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron, 2009, 62, 218-29.
91. Prusiner, S. B. Prions. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 13363-83.
92. Florio, T.; Grimaldi, M.; Scorziello, A.; Salmona, M.; Bugiani, O.; Tagliavini, F.; Forloni, G.; Schettini, G. Intracellular calcium rise through Ltype calcium channels, as molecular mechanism for prion protein fragment 106-126-induced astroglial proliferation. Biochem. Biophys. Res. Commun., 1996, 228, 397-405.
93. Splawski, I.; Timothy, K. W.; Sharpe, L. M.; Decher, N.; Kumar, P.; Bloise, R.; Napolitano, C.; Schwartz, P. J.; Joseph, R. M.; Condouris, K.; Tager- Flusberg, H.; Priori, S. G.; Sanguinetti, M. C.; Keating, M. T. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell, 2004, 119, 19-31.
94. Barrett, C. F.; Tsien, R. W. The Timothy syndrome mutation differentially affects voltage- and calcium-dependent inactivation of CaV1.2 L-type calcium channels. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 2157-62.
95. Erxleben, C.; Liao, Y.; Gentile, S.; Chin, D.; Gomez-Alegria, C.; Mori, Y.; Birnbaumer, L.; Armstrong, D. L. Cyclosporin and Timothy syndrome increase mode 2 gating of CaV1.2 calcium channels through aberrant phosphorylation of S6 helices. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 3932-7.
96. Splawski, I.; Timothy, K. W.; Decher, N.; Kumar, P.; Sachse, F. B.; Beggs, A. H.; Sanguinetti, M. C.; Keating, M. T. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 8089-96; discussion 8086-8.
97. Hemara-Wahanui, A.; Berjukow, S.; Hope, C. I.; Dearden, P. K.; Wu, S. B.; Wilson-Wheeler, J.; Sharp, D. M.; Lundon-Treweek, P.; Clover, G. M.; Hoda, J. C.; Striessnig, J.; Marksteiner, R.; Hering, S.; Maw, M. A. A CACNA1F mutation identified in an X-linked retinal disorder shifts the voltage dependence of Cav1.4 channel activation. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 7553-8.
98. Hope, C. I.; Sharp, D. M.; Hemara-Wahanui, A.; Sissingh, J. I.; Lundon, P.; Mitchell, E. A.; Maw, M. A.; Clover, G. M. Clinical manifestations of a unique X-linked retinal disorder in a large New Zealand family with a novel mutation in CACNA1F, the gene responsible for CSNB2. Clin. Experiment. Ophthalmol., 2005, 33, 129-36.
99. Splawski, I.; Yoo, D. S.; Stotz, S. C.; Cherry, A.; Clapham, D. E.; Keating, M. T. CACNA1H mutations in autism spectrum disorders. J. Biol. Chem., 2006, 281, 22085-91.
100. Ertel, E. A.; Campbell, K. P.; Harpold, M. M.; Hofmann, F.; Mori, Y.; Perez- Reyes, E.; Schwartz, A.; Snutch, T. P.; Tanabe, T.; Birnbaumer, L.; Tsien, R. W.; Catterall, W. A. Nomenclature of voltage-gated calcium channels. Neuron, 2000, 25, 533-5.
101. Perez-Reyes, E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol. Rev., 2003, 83, 117-61.
102. Klockner, U.; Lee, J. H.; Cribbs, L. L.; Daud, A.; Hescheler, J.; Pereverzev, A.; Perez-Reyes, E.; Schneider, T. Comparison of the Ca2 + currents induced by expression of three cloned alpha1 subunits, alpha1G, alpha1H and alpha1I, of low-voltage-activated T-type Ca2 + channels. Eur. J. Neurosci., 1999, 11, 4171-8.
103. Newcomb, R.; Szoke, B.; Palma, A.; Wang, G.; Chen, X.; Hopkins, W.; Cong, R.; Miller, J.; Urge, L.; Tarczy-Hornoch, K.; Loo, J. A.; Dooley, D. J.; Nadasdi, L.; Tsien, R. W.; Lemos, J.; Miljanich, G. Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochemistry, 1998, 37, 15353-62.
104. Choi, D. W. Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci, 1995, 18, 58-60.
105. Franklin, J. L.; Johnson, E. M., Jr. Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends Neurosci, 1992, 15, 501-8.
106. Yagami, T.; Ueda, K.; Sakaeda, T.; Itoh, N.; Sakaguchi, G.; Okamura, N.; Hori, Y.; Fujimoto, M. Protective effects of a selective L-type voltagesensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem. Pharmacol., 2004, 67, 1153-65.
107. Ninomiya, M.; Tani, T.; Nakajima, S.; Ueda, M. Effects of S-312, a new calcium antagonist, on the mechanical and electrophysiological responses of isolated cardiovascular preparations. Jpn J Pharmacol, 1989, 51, 227-38.
108. Takamatsu, H.; Kondo, K.; Ikeda, Y.; Umemura, K. Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion. Eur J Pharmacol, 1998, 362, 137-42.
109. Yagami, T.; Ueda, K.; Asakura, K.; Kuroda, T.; Hata, S.; Sakaeda, T.; Kambayashi, Y.; Fujimoto, M. Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. Brain Res., 2002, 948, 72-81.
110. Yagami, T.; Ueda, K.; Sakaeda, T.; Okamura, N.; Nakazato, H.; Kuroda, T.; Hata, S.; Sakaguchi, G.; Itoh, N.; Hashimoto, Y.; Fujimoto, M. Effects of an endothelin B receptor agonist on secretory phospholipase A2-IIA-induced apoptosis in cortical neurons. Neuropharmacology, 2005, 48, 291-300.
111. Yagami, T.; Nakazato, H.; Ueda, K.; Asakura, K.; Kuroda, T.; Hata, S.; Sakaeda, T.; Sakaguchi, G.; Itoh, N.; Hashimoto, Y.; Hiroshige, T.; Kambayashi, Y. Prostaglandin E2 rescues cortical neurons from amyloid beta protein- induced apoptosis. Brain Res., 2003, 959, 328-35.
112. Yagami, T.; Ueda, K.; Asakura, K.; Sakaeda, T.; Nakazato, H.; Kuroda, T.; Hata, S.; Sakaguchi, G.; Itoh, N.; Nakano, T.; Kambayashi, Y.; Tsuzuki, H. Gas6 rescues cortical neurons from amyloid beta protein-induced apoptosis. Neuropharmacology, 2002, 43, 1289-96.
113. Yagami, T.; Ueda, K.; Asakura, K.; Okamura, N.; Sakaeda, T.; Sakaguchi, G.; Itoh, N.; Hashimoto, Y.; Nakano, T.; Fujimoto, M. Effect of Gas6 on secretory phospholipase A(2)-IIA-induced apoptosis in cortical neurons. Brain Res., 2003, 985, 142-9.
114. Funakoshi, H.; Yonemasu, T.; Nakano, T.; Matumoto, K.; Nakamura, T. Identification of Gas6, a putative ligand for Sky and Axl receptor tyrosine kinases, as a novel neurotrophic factor for hippocampal neurons. J Neurosci Res, 2002, 68, 150-60.
115. Wetsel, W. C.; Khan, W. A.; Merchenthaler, I.; Rivera, H.; Halpern, A. E.; Phung, H. M.; Negro-Vilar, A.; Hannun, Y. A. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol, 1992, 117, 121-33.
116. Zhang, Y.; Jiang, D.; Zhang, J.; Wang, F.; Jiang, X.; Tao, J. Activation of neuromedin U type 1 receptor inhibits L-type Ca2+ channel currents via phosphatidylinositol 3-kinase-dependent protein kinase C epsilon pathway in mouse hippocampal neurons. Cell Signal, 2010, 22, 1660-8.
117. Pfeiffer, R. F. Parkinson disease: calcium channel blockers and Parkinson disease. Nat Rev Neurol, 2010, 6, 188-9.
118. Forette, F.; Seux, M. L.; Staessen, J. A.; Thijs, L.; Birkenhager, W. H.; Babarskiene, M. R.; Babeanu, S.; Bossini, A.; Gil-Extremera, B.; Girerd, X.; Laks, T.; Lilov, E.; Moisseyev, V.; Tuomilehto, J.; Vanhanen, H.; Webster, J.; Yodfat, Y.; Fagard, R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet, 1998, 352, 1347-51.
119. Lopez-Arrieta, J. M.; Birks, J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev, 2002, CD000147.
120. Facchinetti, F.; Fasolato, C.; Del Giudice, E.; Burgo, A.; Furegato, S.; Fusco, M.; Basso, E.; Seraglia, R.; D'Arrigo, A.; Leon, A. Nimodipine selectively stimulates beta-amyloid 1-42 secretion by a mechanism independent of calcium influx blockage. Neurobiol Aging, 2006, 27, 218-27.
121. Lu, Z.; Jiang, Y. P.; Ballou, L. M.; Cohen, I. S.; Lin, R. Z. Galpha q inhibits cardiac L-type Ca2+ channels through phosphatidylinositol 3-kinase. J. Biol. Chem., 2005, 280, 40347-54.